Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin
delivery and diabetes technology company, today announced its
schedule of presentations for the American Diabetes Association’s
(ADA) 84th Scientific Sessions taking place in Orlando, Florida
from June 21-24.
Product Theater
The Company will host a Product Theater on Saturday, June 22
from 10:15 am - 11:00 am EDT at Product Theater #1.
Meet Tandem Mobi: Tiny pump, big control. The future of
Automated Insulin Delivery (AID)
Presenters:
- Jordan Pinsker, MD, Chief Medical Officer at Tandem Diabetes
Care
- Halis Kaan Akturk, MD, Associate Professor of Medicine and
Pediatrics at the Barbara Davis Center for Diabetes, University of
Colorado
- Cari Berget, MPH, RN, CDCES, Director of the PANTHER Program
and Research Instructor in Pediatrics at Barbara Davis Center
During this session, new early user insights will be presented
on Tandem Mobi, the world’s smallest, durable AID system* that
became commercially available in the United States in February of
2024. Presenters will discuss how the unique wearability features
of Tandem Mobi combined with the Control-IQ algorithm ushers in a
new generation of AID systems. The speakers will also cover the
benefits of a small-sized insulin delivery system that allows the
ability to disconnect for sports, swimming, and real-life
scenarios, and how optimizing algorithm settings can help improve
patient outcomes.
“This groundbreaking data is the first presentation of Tandem
Mobi user insights and demonstrate our continued commitment to
advancing diabetes care through innovative technology,” said Dr.
Pinsker. “Understanding these early Tandem Mobi insights is
critical to help ensure our portfolio of diabetes solutions
continues to create a positively different experience for our
customers.”
Poster Presentations
From June 22 - June 24, the Company will also release data
during the Poster Sessions in the Poster Hall. Tandem authors will
be available for questions during the General Poster Sessions
scheduled for Saturday, June 22 at 12:30 pm EDT.
- The t:slim X2 with Control-IQ Technology Overcomes Missed
Boluses for Moderate Meals
Tandem Diabetes
Care Authors: Larry Fu,
Principal Data Scientist; Alex Trahan, Sr. Manager, Data Science;
Laurel Messer, PhD, MPH, RN, CDCES, Sr. Director of Medical
Affairs; and Alex Constantin, PhD, Sr. Director, Data Science
- What Happens When People Don’t Bolus for Extended Periods of
Time while Using the t:slim X2 with Control-IQ Technology?
Tandem Diabetes
Care Authors: Miranda R. Polin,
Sr. Data Analyst II; Andy Johnson, Principal Data Analyst/Manager;
Laurel Messer, PhD, MPH, RN, CDCES, Sr. Director of Medical
Affairs; Alex Constantin, PhD, Sr. Director, Data Science; and
Jordan Pinsker, MD, Chief Medical Officer
- High Time in Closed Loop for Control-IQ Technology with New
Interoperable iCGM Sensor
Tandem Diabetes Care
Authors: Steph Habif, EdD, MS; Sabah Mufti, Senior Manager,
Product Marketing; Michelle Manning, Principal Customer Feedback
Scientist; Kevin Wu, Sr. Product Manager, Product Management; and
Laurel Messer, PhD, MPH, RN, CDCES, Sr. Director of Medical
Affairs
- High User Satisfaction and Ease of Use Scores with 6 Months
Use of the Tandem t:connect Mobile Application
Tandem Diabetes
Care Authors: Kimia Assadi,
MPH, Sr. Medical Writer I; Michelle Manning, Principal Customer
Feedback Scientist/Manager; Jordan Pinsker, MD, Chief Medical
Officer; and Laurel Messer, PhD, MPH, RN, CDCES, Sr. Director of
Medical Affairs
- New Paradigms for Wearability with the Tandem Mobi System:
Mobi Can Be Worn Many Ways, Early Data Indicate
Tandem Diabetes Care
Authors: Steph Habif, EdD, MS; Michelle Manning, Principal
Customer Feedback Scientist; Scott Leas, Director of Business
Analytics; Lexi Morgan, Product Manager, Commercial Marketing; and
Laurel Messer, PhD, MPH, RN, CDCES, Sr. Director of Medical
Affairs
Exhibitor Information
The Company will also be an exhibitor during the full duration
of ADA at Booth #1621. Tandem Mobi will be available for
demonstration with the recently launched Dexcom G7 Continuous
Glucose Monitoring (CGM) System integration. The t:slim X2, the #1
rated automated insulin delivery system (AID) system**, will also
be on display as the first insulin pump to be compatible with three
CGMs: Dexcom G6, Dexcom G7 and Abbott FreeStyle Libre 2 Plus.
Other Presentations
Dr. Laurel Messer, Sr. Director of Medical Affairs at Tandem
Diabetes Care, will also participate in the “Bridging Technology
and Therapies to Improve Diabetes Outcomes” panel during diaTribe
Musings LIVE on Thursday, June 20 from 5:00 - 7:30 pm EDT at The
Gaylord Palms Resort, Emerald Bay Plaza.
* As of June 2024. Data on file, Tandem Diabetes Care. **
dQ&A US Diabetes Connections Patient Panel Report, Q3 2023
About Tandem Diabetes Care
Tandem Diabetes Care, a global insulin delivery and diabetes
technology company, manufactures and sells advanced automated
insulin delivery systems that reduce the burden of diabetes
management, while creating new possibilities for patients, their
loved ones, and healthcare providers. The Company’s pump portfolio
features the Tandem Mobi system and the t:slim X2 insulin pump,
both of which feature Control-IQ advanced hybrid closed-loop
technology. Tandem Diabetes Care is based in San Diego, California.
For more information, visit tandemdiabetes.com.
Follow Tandem Diabetes Care on X @tandemdiabetes; use #tslimX2
#TandemMobi and #TandemDiabetes.
Follow Tandem Diabetes Care on Facebook at
www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at
https://www.linkedin.com/company/tandemdiabetes.
© 2024 Tandem Diabetes Care, Inc. All rights reserved. Tandem
Diabetes Care, Tandem logos, Control-IQ, t:slim X2, and Tandem Mobi
are trademarks of Tandem Diabetes Care, Inc. in the United States
and/or other countries. Dexcom, Dexcom G6, and Dexcom G7 are either
registered trademarks or trademarks of Dexcom, Inc. in the United
States and/or other countries. FreeStyle, Libre, and related brand
marks are marks of Abbott and used with permission. All other
third-party marks are the property of their respective owners.
Responsible Use of Control-IQ technology
Control-IQ technology does not prevent all highs and lows. Users
must still bolus for meals and actively manage their diabetes.
Visit tandemdiabetes.com/responsible-use for additional important
safety information.
Important Safety Information
RX ONLY. Indications for Use: Tandem Mobi
system: The Tandem Mobi insulin pump with interoperable
technology (the pump) is intended for the subcutaneous delivery of
insulin, at set and variable rates, for the management of diabetes
mellitus in persons requiring insulin. The pump is able to reliably
and securely communicate with compatible, digitally connected
devices, including automated insulin dosing software, to receive,
execute, and confirm commands from these devices. The pump is
intended for single patient, home use and requires a prescription.
The pump is indicated for use in individuals 6 years of age and
greater. t:slim X2 insulin pump: The
t:slim X2 insulin pump with interoperable technology is intended
for the subcutaneous delivery of insulin, at set and variable
rates, for the management of diabetes mellitus in people requiring
insulin. The pump is able to reliably and securely communicate with
compatible, digitally connected devices, including automated
insulin dosing software, to receive, execute, and confirm commands
from these devices. The pump is intended for single patient use.
The pump is indicated for use with NovoLog or Humalog U-100
insulin. The pump is indicated for use in individuals 6 years of
age and greater. Control-IQ
technology: Control-IQ technology is intended for use with
compatible integrated continuous glucose monitors (iCGM, sold
separately) and alternate controller enabled (ACE) pumps to
automatically increase, decrease, and suspend delivery of basal
insulin based on iCGM readings and predicted glucose values. It can
also deliver correction boluses when the glucose value is predicted
to exceed a predefined threshold. Control-IQ technology is intended
for the management of Type 1 diabetes mellitus in persons 6 years
of age and greater. Control-IQ technology is intended for single
patient use. Control-IQ technology is indicated for use with
NovoLog or Humalog U-100 insulin.
WARNING: Control-IQ technology should not be used by anyone
under the age of 6 years old. It should also not be used in
patients who require less than 10 units of insulin per day or who
weigh less than 55 pounds.
Control-IQ technology is not indicated for use in pregnant
women, people on dialysis, or critically ill patients. Do not use
Control-IQ technology if using hydroxyurea. Users of a Tandem
insulin pump and Control-IQ technology must use the insulin pump,
CGM, and all other system components in accordance with their
respective instructions for use; test blood glucose levels as
recommended by their healthcare provider; demonstrate adequate
carb-counting skills; maintain sufficient diabetes self-care
skills; see healthcare provider(s) regularly; and have adequate
vision and/or hearing to recognize all functions of the pump,
including alerts, alarms, and reminders. The Tandem pump and the
CGM transmitter and sensor must be removed before MRI, CT, or
diathermy treatment. Visit tandemdiabetes.com/safetyinfo for
additional important safety information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240618093195/en/
Media Contact: 858-366-6900 media@tandemdiabetes.com
Investor Contact: 858-366-6900 IR@tandemdiabetes.com
Grafico Azioni Tandem Diabetes Care (NASDAQ:TNDM)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Tandem Diabetes Care (NASDAQ:TNDM)
Storico
Da Gen 2024 a Gen 2025
